Immunome stock
IMNMNASDAQImmunome, Inc., HealthcareISIN US45257U1088
36Score 36 out of 100, Weak
Price and trend
45 / 100
Price history
+7.3% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 37% below its 52-week high. Largest decline in 6 years: 95% (February 2021 to December 2022).
Chart figures for advanced users
- SMA 50$20.82
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.24
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.47
- The lowest closing price of the last twelve months.
- Resistance$29.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Immunome, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.21B, is number 118 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6.94M (down 23.2% year on year) and a loss of $212.39M.
- For fiscal 2026, analysts expect on average revenue of $307.69K (down 95.6%) and adjusted earnings per share of −$2.36.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 596 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $653.48M, financial debt $3.86M.Stability 70
Weaknesses
- Loss-makingLoss of $212.39M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$200.6M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 61% a year over the last 12 months.
Its standout strength is stability, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 37 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 23.2% on the prior year. Revenue turned from negative at the start of the period to positive ($6.94M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 57%, operating −3085%, net −3060%. Last 12 months: net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 9 Nov 2026EPS reported −$0.76 (expected −$0.62)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.4% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.36−2.3%
- Revenue
- $307.69K−7.7%
- Earnings per share
- −$2.51−3.4%
- Revenue
- $48.67M−6.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $103,500 in total. 5 insiders sold, $16.01M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Higgins JackSale
11 Sept 2026, Chief Scientific Officer
- Shares
- 13,200
- Price
- $25.32
- Value
- $334,224
- Barchas IsaacSale
12 Aug 2026, Board
- Shares
- 11,048
- Price
- $27.25
- Value
- $301,058
- Barchas IsaacSale
11 Aug 2026, Board
- Shares
- 62,291
- Price
- $26.23
- Value
- $1.63M
Show 15 more
- Barchas IsaacSale
10 Aug 2026, Board
- Shares
- 10,125
- Price
- $26.07
- Value
- $263,959
- Barchas IsaacSale
7 Aug 2026, Board
- Shares
- 15,248
- Price
- $26.06
- Value
- $397,363
- Barchas IsaacSale
6 Aug 2026, Board
- Shares
- 20,840
- Price
- $26.06
- Value
- $543,090
- Horn KinneySale
4 Aug 2026, CHIEF BUSINESS OFFICER
- Shares
- 90,616
- Price
- $25.09
- Value
- $2.27M
- Horn KinneySale
7 Jul 2026, CHIEF BUSINESS OFFICER
- Shares
- 1,092
- Price
- $25.00
- Value
- $27,300
- Barchas IsaacSale
7 Jul 2026, Board
- Shares
- 16,906
- Price
- $24.20
- Value
- $409,125
- Barchas IsaacSale
6 Jul 2026, Board
- Shares
- 83,094
- Price
- $24.11
- Value
- $2M
- Lechleider RobertSale
2 Jul 2026, Chief Medical Officer
- Shares
- 55,000
- Price
- $22.62
- Value
- $1.24M
- Barchas IsaacSale
2 Jul 2026, Board
- Shares
- 100,000
- Price
- $22.59
- Value
- $2.26M
- Barchas IsaacSale
30 Jun 2026, Board
- Shares
- 101,050
- Price
- $21.12
- Value
- $2.13M
- Lechleider RobertSale
25 Jun 2026, Chief Medical Officer
- Shares
- 55,000
- Price
- $19.85
- Value
- $1.09M
- Rosett MaxSale
15 Jun 2026, Chief Financial Officer
- Shares
- 60,000
- Price
- $18.23
- Value
- $1.09M
- Bienaime Jean JacquesPurchase
5 Jun 2026, Board
- Shares
- 10,500
- Price
- $19.45
- Value
- $204,260
- Bienaime Jean JacquesSale
5 Jun 2026, Board
- Shares
- 10,500
- Price
- $19.41
- Value
- $203,820
- Bienaime Jean JacquesPurchase
15 May 2026, Board
- Shares
- 5,000
- Price
- $20.70
- Value
- $103,500
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Immunome
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Replimune GroupREPL $2.31B42
- Lakefront BiotherapeuticsLKFT $2.26B74
- Celldex TherapeuticsCLDX $2.24B34
- Palvella TherapeuticsPVLA $2.24B44
- Alamar BiosciencesALMR $2.21B47
- Maze TherapeuticsMAZE $2.2B45
- Maravai LifeSciences HoldingsMRVI $2.18B38
- Trevi TherapeuticsTRVI $2.18B38
ETFs that hold Immunome
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.20% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.18% | 0.40% | €813.42M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.